Saturday, July 11, 2026

Drug profile · INN

esaxerenone

esaxerenone (MINNEBRO) is a mineralocorticoid receptor antagonist.

PMDA: approved
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — esaxerenone
Class
Route
Patents
0
Programs
0
Data quality
0.78

Quick answer

esaxerenone (MINNEBRO) is a mineralocorticoid receptor antagonist.

Key facts

INN esaxerenone
Brand MINNEBRO
Mechanism Mineralocorticoid receptor antagonist
Target Mineralocorticoid receptor

Mechanism of action

Mineralocorticoid receptor antagonist

Primary target: Mineralocorticoid receptor

Approval history

Authority Status Date
PMDA approved

Related & competitor drugs

  1. spironolactone Cardiovascular system (C03)
  2. desoxycorticosterone acetate Mineralocorticoid receptor agonist
  3. desoxycorticosterone pivalate Mineralocorticoid receptor agonist
  4. drospirenone Progesterone receptor agonist
  5. eplerenone Mineralocorticoid receptor antagonist
  6. felodipine Voltage-gated L-type calcium channel blocker

Frequently asked questions

What is esaxerenone?

esaxerenone (MINNEBRO) is a mineralocorticoid receptor antagonist.

What is the brand name for esaxerenone?

MINNEBRO is a marketed brand name for esaxerenone. Check FDA Drugs@FDA for the current US label holder and prescribing information.